Summary
The effect of galanthamine (GAL) and its 2 major metabolites on human cholinesterases has been explored. Epigalanthamine, a diastereomer of GAL, was 130-times less potent in vitro in its effect on acetylcholinesterase (AChE) in erythrocytes than the parent compound, and it did not differ significantly from the ketone galanthaminone. In vivo, the maximal 36–55% inhibition of AChE was approached 30 min after oral administration of 10 mg GAL. The duration of the catalytic inhibition corresponded to an elimination half-life of approximately 5–7 h. GAL was well tolerated in 8/8 healthy volunteers, and 3/4 Alzheimer patients tolerated the drug up to a daily dose of 40 mg.
This is a preview of subscription content, log in via an institution to check access.
References
Schuh FT (1976) Zum molekularen Wirkmechanismus von Galanthamin, einem Curare-Antagonisten. Anaesthesist 25: 444–448
Thomsen T, Kewitz H (1990) Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 46: 1553–1558
Thomsen T, Bickel U, Fischer JP, Kewitz H (1990) Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1: 46–51
Rainer M, Mark T, Haushofer A (1989) Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer's type. In: Kewitz H, Thomsen T, Bickel U (eds) Pharmacological interventions on central cholinergic mechanisms in senile dementia. Zuckschwerdt, München pp 233–237
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical Diagnosis of Alzheimer's Disease. Report of the NINCDS-ADRDA Work Group Under the Auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944
Tencheva J, Yamboliev I, Zhivkova Z (1987) Reversed phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine. J Chromatogr 421: 396–400
Foldes FF, Smith JC (1966) The interaction of human cholinesterases with anticholinesterases used in the therapy of myasthenia gravis. Ann NY Acad Sci 135: 287–301
Thomsen T, Kewitz H, Pleul O (1988) Estimation of cholinesterase activity (EC 3.1.1.7; 3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring in vivo effects of reversible inhibitors. J Clin Chem Clin Biochem 26: 469–475
Thomsen T, Kewitz H, Pleul O (1989) A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme 42: 219–224
Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, Jovovich V (1989) Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 39: 50–58
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomsen, T., Bickel, U., Fischer, J.P. et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 39, 603–605 (1990). https://doi.org/10.1007/BF00316106
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316106